Login to Your Account



MannKind's Dreams Shattered for Afrezza Inhaled Insulin Nod

By Donna Young


Tuesday, March 16, 2010
The FDA told MannKind Corp. in a complete response letter that before the agency could approve the firm's inhaled diabetes drug Afrezza (insulin human rDNA origin), regulators needed more information about its clinical utility and comparison data about the newer version of the drug's inhaler device vs. the one tested in pivotal clinical trials. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription